{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:57:12Z","timestamp":1793717832056,"version":"4.6.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting. Qualitative study with prison population. Hepatitis C (HCV) treatments with direct-acting antiviral therapy (DAA) are an easy and effective option among people who inject drugs (PWID). However, difficulties in accessing and monitoring treatment in community services and dropouts on release from prison are detected among PWID. For this reason, the aim of the study is to know the access barriers in the diagnosis and treatment of HCV in community health services. An exploratory qualitative study was carried out through semi-structured interviews with 33 PWID recruited in a pre-trial detention prison in Barcelona. The information obtained was analysed using grounded theory. Among PWID sub-population entering prison, personal barriers are related to intense drug use, lack of interest and ignorance of HCV infection and treatment, as well as being in a situation of social exclusion. In relation to health providers, they reported receiving little information, the existence of language barriers in migrants, not receiving screening and treatment proposals, and having poor interactions with some professionals. Systemic barriers were expressed related to the health system circuit being complicated, perceiving little comprehensive care and lack of community support. It is recommended to intensify prevention and treatment campaigns, promoting drug substitution programmes than current ones, improve health education, make the diagnosis and treatment process more flexible, and promote social policies and holistic care for greater coverage of the needs of PWID.<\/jats:p>","DOI":"10.1186\/s12954-024-01009-7","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T09:01:35Z","timestamp":1714208495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting"],"prefix":"10.1186","volume":"21","author":[{"given":"Elena","family":"Yela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar\u00edo","family":"L\u00f3pez Gallegos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Clua-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"key":"1009_CR1","volume-title":"Combating hepatitis B and C to reach elimination by 2030: advocacy brief","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Geneva: World Health Organization; 2016."},{"key":"1009_CR2","volume-title":"Guidelines for the screening, care and treatment of persons with hepatitis C infection","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization; 2016."},{"key":"1009_CR3","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis. World Health Organization. 2016. https:\/\/apps.who.int\/iris\/handle\/10665\/246177, Accessed April 22, 2021."},{"key":"1009_CR4","unstructured":"World Health Organization, Hepatitis C, Geneva. World Health Organization; 2019. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c, Accessed June 14, 2021."},{"issue":"1","key":"1009_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/hex.13400","volume":"25","author":"M Paisi","year":"2022","unstructured":"Paisi M, Crombag N, Burns L, Bogaerts A, Withers L, Bates L, Crowley D, Witton R, Shawe J. Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: a mixed-methods systematic review. Health Expect. 2022;25(1):48\u201360. https:\/\/doi.org\/10.1111\/hex.13400.","journal-title":"Health Expect"},{"key":"1009_CR6","doi-asserted-by":"publisher","first-page":"103247","DOI":"10.1016\/j.drugpo.2021.103247","volume":"96","author":"A Amoako","year":"2021","unstructured":"Amoako A, Ortiz-Paredes D, Engler K, Lebouch\u00e9 B, Klein MB. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: a knowledge synthesis. Int J Drug Policy. 2021;96:103247. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103247.","journal-title":"Int J Drug Policy"},{"key":"1009_CR7","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.drugpo.2014.08.014","volume":"26","author":"P Bruggmann","year":"2015","unstructured":"Bruggmann P, Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26:S22\u20136.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"1009_CR8","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/jvh.12940","volume":"25","author":"A Marco","year":"2018","unstructured":"Marco A, Roget M, Cervantes M, Forn\u00e9 M, Planella R, Miquel M, Ortiz J, Navarro M, Gallego C, Vergara M, Out of Prison Study Group. Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates. J Viral Hepat. 2018;25(11):1280\u20136.","journal-title":"J Viral Hepat"},{"key":"1009_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.drugpo.2018.09.008","volume":"62","author":"C Folch","year":"2018","unstructured":"Folch C, Lorente N, Maj\u00f3 X, Par\u00e9s-Badell O, Roca X, Brugal T, Roux P, Carrieri P, Colom J, Casabona J. REDAN study group. Drug consumption rooms in Catalonia: a comprehensive evaluation of social, health and harm reduction benefits. Int J Drug Policy. 2018;62:24\u20139.","journal-title":"Int J Drug Policy"},{"key":"1009_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jsat.2017.03.003","volume":"77","author":"O Par\u00e9s-Badell","year":"2017","unstructured":"Par\u00e9s-Badell O, Espelt A, Folch C, Maj\u00f3 X, Gonz\u00e1lez V, Casabona J, Brugal MT. Undiagnosed HIV and Hepatitis C infection in people who inject drugs: from new evidence to better practice. J Subst Abuse Treat. 2017;77:13\u201320.","journal-title":"J Subst Abuse Treat"},{"key":"1009_CR11","doi-asserted-by":"publisher","first-page":"103057","DOI":"10.1016\/j.drugpo.2020.103057","volume":"10","author":"C Folch","year":"2021","unstructured":"Folch C, Saludes V, Reyes-Ure\u00f1a J, Antuori A, Ib\u00e1\u00f1ez N, Maj\u00f3 X, Colom J, Matas L, Casabona J, Martr\u00f3 E, HepCdetect II Study Group. The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: major gaps for migrants. Int J Drug Policy. 2021;10:90:103057.","journal-title":"Int J Drug Policy"},{"key":"1009_CR12","unstructured":"Comissi\u00f3 per a l\u2019elaboraci\u00f3 del pla de prevenci\u00f3 i control de l\u2019hepatitis C a Catalunya. 2019. Generalitat de Catalunya. Departament de Salut. https:\/\/salutpublica.gencat.cat\/web\/.content\/minisite\/aspcat\/vigilancia_salut_publica\/vih-sida-its\/04_Hepatitis_viriques\/Pla-Hepatitis-Definitiu_C_DEF.pdf, Accessed May 10, 2021."},{"key":"1009_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.drugpo.2019.10.012","volume":"74","author":"V Saludes","year":"2019","unstructured":"Saludes V, Antuori A, Folch C, Gonz\u00e1lez N, Ib\u00e1\u00f1ez N, Maj\u00f3 X, Colom J, Matas L, Casabona J, Martr\u00f3 E, HepCdetect II Study Group. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia. Int J Drug Policy. 2019;74:236\u201345.","journal-title":"Int J Drug Policy"},{"key":"1009_CR14","volume-title":"Protocol de diagn\u00f2stic i tractament del virus de l\u2019hepatitis C per persones drogodependents","author":"Ag\u00e8ncia de Salut P\u00fablica de Catalunya","year":"2021","unstructured":"Ag\u00e8ncia de Salut P\u00fablica de Catalunya. Programa De prevenci\u00f3, control i atenci\u00f3 Al virus d\u2019immunodefici\u00e8ncia humana, les infeccions de transmissi\u00f3 sexual (ITS) i les hepatitis v\u00edriques (HV). Protocol de diagn\u00f2stic i tractament del virus de l\u2019hepatitis C per persones drogodependents. Barcelona: Ag\u00e8ncia de Salut P\u00fablica de Catalunya; 2021."},{"issue":"1","key":"1009_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12954-019-0290-x","volume":"16","author":"JM Peric\u00e0s","year":"2019","unstructured":"Peric\u00e0s JM, Bromberg DJ, Ocampo D, Schatz E, Wawer I, Wysocki P, Safreed-Harmon K, Lazarus JV. Hepatitis C services at harm reduction centres in the European Union: a 28-country survey. Harm Reduct J. 2019;16(1):20. https:\/\/doi.org\/10.1186\/s12954-019-0290-x.","journal-title":"Harm Reduct J"},{"key":"1009_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41124-018-0035-6","volume":"3","author":"V Belackova","year":"2018","unstructured":"Belackova V, Salmon AM, Schatz E, Jauncey M. Drug consumption rooms (DCRs) as a setting to address hepatitis C - findings from an international online survey. Hepatol Med Policy. 2018;3:9. https:\/\/doi.org\/10.1186\/s41124-018-0035-6.","journal-title":"Hepatol Med Policy"},{"key":"1009_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.drugpo.2019.05.014","volume":"72","author":"A Marco","year":"2019","unstructured":"Marco A, Guerrero RA, Vergara M, Gallego C, Sol\u00e9 C, Planella R, Vaz ME, Teixid\u00f3 N, Sastre A, Touz\u00f3n C, da Silva A, Almada G, Ru\u00edz A, Cayl\u00e0 JA, Turu E. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002\u20132016. Int J Drug Policy. 2019;72:189\u201394.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1009_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.37201\/req\/001.2022","volume":"35","author":"RJ Tejera-P\u00e9rez","year":"2022","unstructured":"Tejera-P\u00e9rez RJ, Iglesias-G\u00f3mez A, Oliva-Oliva A, Rodr\u00edguez-Alonso B, Alonso-Sard\u00f3n M, S\u00e1nchez Ledesma M, Carbonell-Mu\u00f1oz C, Pendones Ulerio J, Mu\u00f1oz-Bellido JL, Belhassen-Garc\u00eda M. Real-life experience of hepatitis C treatment in a Spanish prison. Rev Esp Quimioter. 2022;35(3):273\u20138. https:\/\/doi.org\/10.37201\/req\/001.2022.","journal-title":"Rev Esp Quimioter"},{"issue":"1","key":"1009_CR19","first-page":"75","volume":"46","author":"R Clua","year":"2021","unstructured":"Clua R. Razones de las pr\u00e1cticas de riesgo en usuarios de drogas por v\u00eda parenteral de programas de reducci\u00f3n de da\u00f1os en Barcelona. Revista Espa\u00f1ola De Drogodependencias. 2021;46(1):75\u201389.","journal-title":"Revista Espa\u00f1ola De Drogodependencias"},{"key":"1009_CR20","unstructured":"Marco A, Yela E, Bullich C, Freixenet X, Guerrero RA, Turu E, GRUMIP. Infecci\u00f3n por VHC conocida y oculta en los ingresados en las prisiones de Catalu\u00f1a. Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. 2019; 37(especial congreso 2):3."},{"key":"1009_CR21","unstructured":"Saludes V, Marco A, Bordoy AE, Yela E, Tur\u00fa E, Not A, L\u00f3pez-Corbeto E, Egea-Cort\u00e9s L, Casabona J, GRUMIP, Martr\u00f3 E. HCV reinfection is common in people entering prisons in Catalonia, Spain (Re-HCV study). The International Network on Health and Hepatitis in Substance Users (INHSU); 2021."},{"issue":"3","key":"1009_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4321\/S1575-06202019000300006","volume":"21","author":"E Turu","year":"2019","unstructured":"Turu E, Barn\u00e9s I, Marco A. Asistencial and therapeutic continuity after release from prison: an urgent problem that requires solutions. The model applied in Catalonian prisons. Rev Esp Sanid Penit. 2019;21(3):153\u201360.","journal-title":"Rev Esp Sanid Penit"},{"issue":"2","key":"1009_CR23","doi-asserted-by":"publisher","first-page":"e000057","DOI":"10.1136\/fmch-2018-000057","volume":"7","author":"M DeJonckheere","year":"2019","unstructured":"DeJonckheere M, Vaughn LM. Semistructured interviewing in primary care research: a balance of relationship and rigour. Family Med Community Health. 2019;7(2):e000057. https:\/\/doi.org\/10.1136\/fmch-2018-000057.","journal-title":"Family Med Community Health"},{"key":"1009_CR24","doi-asserted-by":"publisher","DOI":"10.46743\/2160-3715\/2015.2281","author":"PI Fusch","year":"2015","unstructured":"Fusch PI, Ness LR. Qualitative Rep. 2015;20(9):1408\u201316. https:\/\/doi.org\/10.46743\/2160-3715\/2015.2281. Are We There Yet? Data Saturation in Qualitative Research."},{"key":"1009_CR25","doi-asserted-by":"publisher","first-page":"108460","DOI":"10.1016\/j.jsat.2021.108460","volume":"127","author":"E Heard","year":"2021","unstructured":"Heard E, Smirnov A, Massi L, Selvey LA. Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: experiences of patients who inject drugs accessing treatment in general practice settings in Australia. J Subst Abuse Treat. 2021;127:108460. https:\/\/doi.org\/10.1016\/j.jsat.2021.108460.","journal-title":"J Subst Abuse Treat"},{"key":"1009_CR26","volume-title":"The discovery of grounded theory: strategies for qualitative research","author":"BG Glaser","year":"1967","unstructured":"Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. Chicago: Aldine Publshing; 1967."},{"key":"1009_CR27","volume-title":"Constructing grounded theory: a practical guide through qualitative analysis","author":"K Charmaz","year":"2006","unstructured":"Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis. London: Sage; 2006."},{"issue":"5","key":"1009_CR28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1188\/14.ONF.545-547","volume":"41","author":"N Carter","year":"2014","unstructured":"Carter N, Bryant-Lukosius D, DiCenso A, Blythe J, Neville AJ. The use of triangulation in qualitative research. Oncol Nurs Forum. 2014;41(5):545\u20137. https:\/\/doi.org\/10.1188\/14.ONF.545-547.","journal-title":"Oncol Nurs Forum"},{"key":"1009_CR29","doi-asserted-by":"publisher","first-page":"e3041","DOI":"10.18294\/sc.2021.3041","volume":"17","author":"A Llort Su\u00e1rez","year":"2021","unstructured":"Llort Su\u00e1rez A, Clua-Garc\u00eda R. Public policies for people who use drugs: strategies for the elimination of stigma and the promotion of human rights. Salud Colect. 2021;17:e3041. https:\/\/doi.org\/10.18294\/sc.2021.3041.","journal-title":"Salud Colect"},{"issue":"1","key":"1009_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1001\/jamainternmed.2023.6035","volume":"184","author":"ME Tinetti","year":"2024","unstructured":"Tinetti ME, Hladek MD, Ejem D. One size fits All-An Underappreciated Health Inequity. JAMA Intern Med. 2024;184(1):7\u20138. https:\/\/doi.org\/10.1001\/jamainternmed.2023.6035.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"1009_CR31","doi-asserted-by":"publisher","first-page":"e0207226","DOI":"10.1371\/journal.pone.0207226","volume":"13","author":"A Madden","year":"2018","unstructured":"Madden A, Hopwood M, Neale J, Treloar C. Beyond interferon side effects: what residual barriers exist to DAA Hepatitis C treatment for people who inject drugs? PLoS ONE. 2018;13(11):e0207226. https:\/\/doi.org\/10.1371\/journal.pone.0207226.","journal-title":"PLoS ONE"},{"issue":"1","key":"1009_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12954-021-00580-7","volume":"18","author":"NT Ludwig-Barron","year":"2021","unstructured":"Ludwig-Barron NT, Guthrie BL, Mbogo L, Bukusi D, Sinkele W, Gitau E, Farquhar C, Monroe-Wise A. Barriers and facilitators of HIV and Hepatitis C care among people who inject drugs in Nairobi, Kenya: a qualitative study with peer educators. Harm Reduct J. 2021;18(1):133. https:\/\/doi.org\/10.1186\/s12954-021-00580-7.","journal-title":"Harm Reduct J"},{"issue":"4","key":"1009_CR33","first-page":"229","volume":"9","author":"O Massah","year":"2017","unstructured":"Massah O, Effatpanah M, Moradi A, Salehi M, Farhoudian A, Karami Z. Barriers to Hepatitis C Treatment among women in Methadone Treatment: a study from Iran, the most populous Persian Gulf Country. Addict Health. 2017;9(4):229\u201336.","journal-title":"Addict Health"},{"issue":"4","key":"1009_CR34","doi-asserted-by":"publisher","first-page":"e0216123","DOI":"10.1371\/journal.pone.0216123","volume":"14","author":"I Chikovani","year":"2019","unstructured":"Chikovani I, Ompad DC, Uchaneishvili M, Sulaberidze L, Sikharulidze K, Hagan H, Van Devanter NL. On the way to Hepatitis C elimination in the Republic of Georgia-barriers and facilitators for people who inject drugs for engaging in the treatment program: a formative qualitative study. PLoS ONE. 2019;14(4):e0216123. https:\/\/doi.org\/10.1371\/journal.pone.0216123.","journal-title":"PLoS ONE"},{"issue":"1","key":"1009_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12954-019-0286-6","volume":"16","author":"E Childs","year":"2019","unstructured":"Childs E, Assoumou SA, Biello KB, Biancarelli DL, Drainoni ML, Edeza A, Salhaney P, Mimiaga MJ, Bazzi AR. Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs. Harm Reduct J. 2019;16(1):14. https:\/\/doi.org\/10.1186\/s12954-019-0286-6.","journal-title":"Harm Reduct J"},{"issue":"5","key":"1009_CR36","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/jvh.13259","volume":"27","author":"D Pourmarzi","year":"2020","unstructured":"Pourmarzi D, Smirnov A, Hall L, Thompson H, FitzGerald G, Rahman T. Enablers and barriers for the provision of community-based HCV treatment: a case study of a real-world practice. J Viral Hepat. 2020;27(5):484\u201396. https:\/\/doi.org\/10.1111\/jvh.13259.","journal-title":"J Viral Hepat"},{"issue":"1","key":"1009_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12954-018-0269-z","volume":"15","author":"D Crowley","year":"2018","unstructured":"Crowley D, Van Hout MC, Lambert JS, Kelly E, Murphy C, Cullen W. Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners\u2019 perspective. Harm Reduct J. 2018;15(1):62. https:\/\/doi.org\/10.1186\/s12954-018-0269-z.","journal-title":"Harm Reduct J"},{"issue":"4","key":"1009_CR38","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1093\/pubmed\/fdz045","volume":"41","author":"TM N\u00e1poles","year":"2019","unstructured":"N\u00e1poles TM, Batchelder AW, Lin A, Moran L, Johnson MO, Shumway M, Luetkemeyer AF, Peters MG, Eagen KV, Riley ED. HCV treatment barriers among HIV\/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era. J Public Health (Oxf). 2019;41(4):e283\u20139. https:\/\/doi.org\/10.1093\/pubmed\/fdz045.","journal-title":"J Public Health (Oxf)"},{"issue":"3","key":"1009_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.17730\/humo.63.3.h1phxbhrb7m4mlv0","volume":"63","author":"P Bourgois","year":"2004","unstructured":"Bourgois P, Prince B, Moss A. The Everyday violence of Hepatitis C among Young Women who inject drugs in San Francisco. Hum Organ. 2004;63(3):253\u201364. https:\/\/doi.org\/10.17730\/humo.63.3.h1phxbhrb7m4mlv0.","journal-title":"Hum Organ"},{"issue":"1","key":"1009_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12954-020-00429-5","volume":"17","author":"S Shirley-Beavan","year":"2020","unstructured":"Shirley-Beavan S, Roig A, Burke-Shyne N, Daniels C, Csak R. Women and barriers to harm reduction services: a literature review and initial findings from a qualitative study in Barcelona, Spain. Harm Reduct J. 2020;17(1):78. https:\/\/doi.org\/10.1186\/s12954-020-00429-5.","journal-title":"Harm Reduct J"},{"key":"1009_CR41","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.drugalcdep.2018.06.013","volume":"190","author":"MR Skeer","year":"2018","unstructured":"Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. Hep C\u2019s like the common cold\u2019: understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;190:246\u201354. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.06.013.","journal-title":"Drug Alcohol Depend"},{"key":"1009_CR42","doi-asserted-by":"publisher","unstructured":"Sarasa-Renedo A, Espelt A, Folch C, Vecino C, Maj\u00f3 X, Castellano Y, Casabona J, Brugal MT, Redan Study Group. Overdose prevention in injecting opioid users: the role of substance abuse treatment and training programs. Gac Sanit. 2014 Mar-Apr;28(2):146\u201354. https:\/\/doi.org\/10.1016\/j.gaceta.2013.10.012.","DOI":"10.1016\/j.gaceta.2013.10.012"},{"issue":"1","key":"1009_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12954-020-00382-3","volume":"17","author":"A Versfeld","year":"2020","unstructured":"Versfeld A, McBride A, Scheibe A, Spearman CW. Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities. Harm Reduct J. 2020;17(1):39. https:\/\/doi.org\/10.1186\/s12954-020-00382-3.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1009_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12954-021-00480-w","volume":"18","author":"D Jamin","year":"2021","unstructured":"Jamin D, Vanderplasschen W, Sys O, Jauffret-Roustide M, Michel L, Trouiller P, Neisa A, Homen M, Mendes V, St\u00f6ver H. My first 48 hours out: drug users\u2019 perspectives on challenges and strategies upon release from prison. Harm Reduct J. 2021;18(1):32. https:\/\/doi.org\/10.1186\/s12954-021-00480-w.","journal-title":"Harm Reduct J"},{"key":"1009_CR45","doi-asserted-by":"publisher","first-page":"109869","DOI":"10.1016\/j.drugalcdep.2023.109869","volume":"247","author":"R McNair","year":"2023","unstructured":"McNair R, Monaghan M, Montgomery P. Heroin assisted treatment for key health outcomes in people with chronic heroin addictions: a context-focused systematic review. Drug Alcohol Depend. 2023;247:109869. https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.109869.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"1009_CR46","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/add.15601","volume":"117","author":"R Smart","year":"2022","unstructured":"Smart R, Reuter P. Does heroin-assisted treatment reduce crime? A review of randomized-controlled trials. Addiction. 2022;117(3):518\u201331. https:\/\/doi.org\/10.1111\/add.15601.","journal-title":"Addiction"},{"key":"1009_CR47","doi-asserted-by":"publisher","first-page":"102769","DOI":"10.1016\/j.drugpo.2020.102769","volume":"80","author":"A Ivsins","year":"2020","unstructured":"Ivsins A, Boyd J, Beletsky L, McNeil R. Tackling the overdose crisis: the role of safe supply. Int J Drug Policy. 2020;80:102769. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102769.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1009_CR48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12954-019-0351-1","volume":"17","author":"T Fleming","year":"2020","unstructured":"Fleming T, Barker A, Ivsins A, Vakharia S, McNeil R. Stimulant safe supply: a potential opportunity to respond to the overdose epidemic. Harm Reduct J. 2020;17(1):6. https:\/\/doi.org\/10.1186\/s12954-019-0351-1. Published 2020 Jan 10.","journal-title":"Harm Reduct J"},{"key":"1009_CR49","doi-asserted-by":"publisher","first-page":"100490","DOI":"10.1016\/j.lana.2023.100490","volume":"22","author":"B Lettner","year":"2023","unstructured":"Lettner B, Mason K, Greenwald ZR, et al. Rapid Hepatitis C virus point-of-care RNA testing and treatment at an integrated supervised consumption service in Toronto, Canada: a prospective, observational cohort study. Lancet Reg Health Am. 2023;22:100490. https:\/\/doi.org\/10.1016\/j.lana.2023.100490. Published 2023 May 17.","journal-title":"Lancet Reg Health Am"},{"issue":"1","key":"1009_CR50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12954-017-0192-8","volume":"14","author":"AW Batchelder","year":"2017","unstructured":"Batchelder AW, Cockerham-Colas L, Peyser D, Reynoso SP, Soloway I, Litwin AH. Perceived benefits of the hepatitis C peer educators: a qualitative investigation. Harm Reduct J. 2017;14(1):67. https:\/\/doi.org\/10.1186\/s12954-017-0192-8.","journal-title":"Harm Reduct J"},{"key":"1009_CR51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.drugpo.2017.08.004","volume":"50","author":"C Henderson","year":"2017","unstructured":"Henderson C, Madden A, Kelsall J. Beyond the willing & the waiting\u2019 - the role of peer-based approaches in hepatitis C diagnosis & treatment. Int J Drug Policy. 2017;50:111\u20135. https:\/\/doi.org\/10.1016\/j.drugpo.2017.08.004.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"1009_CR52","doi-asserted-by":"publisher","first-page":"e0254729","DOI":"10.1371\/journal.pone.0254729","volume":"16","author":"JA Miler","year":"2021","unstructured":"Miler JA, Carver H, Masterton W, et al. What treatment and services are effective for people who are homeless and use drugs? A systematic \u2018review of reviews\u2019. PLoS ONE. 2021;16(7):e0254729. https:\/\/doi.org\/10.1371\/journal.pone.0254729. Published 2021 Jul 14.","journal-title":"PLoS ONE"},{"issue":"9","key":"1009_CR53","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1080\/10826084.2017.1416404","volume":"53","author":"JS Melo","year":"2018","unstructured":"Melo JS, Mittal ML, Horyniak D, Strathdee SA, Werb D. Injection Drug Use trajectories among migrant populations: a narrative review. Subst Use Misuse. 2018;53(9):1558\u201370. https:\/\/doi.org\/10.1080\/10826084.2017.1416404.","journal-title":"Subst Use Misuse"},{"issue":"7\u20138","key":"1009_CR54","doi-asserted-by":"publisher","first-page":"166","DOI":"10.14745\/ccdr.v44i78a03","volume":"44","author":"N Shehata","year":"2018","unstructured":"Shehata N, Austin T, Ha S, Timmerman K. Barriers to and facilitators of hepatitis C virus screening and testing: a scoping review. Can Commun Dis Rep. 2018;44(7\u20138):166\u201372. https:\/\/doi.org\/10.14745\/ccdr.v44i78a03.","journal-title":"Can Commun Dis Rep"},{"key":"1009_CR55","unstructured":"Direcci\u00f3 General de Serveis Penitenciaris (DGSP). Descriptors estad\u00edstics serveis penitenciaris. Barcelona: Direcci\u00f3 General de Serveis Penitenciaris (DGSP) http:\/\/www.gencat.cat\/justicia\/estadistiques_serveis_penitenciaris\/3_pob.html, Accessed May 24, 2022."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01009-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01009-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01009-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T09:05:32Z","timestamp":1714208732000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01009-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01009-7","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,27]]},"assertion":[{"value":"7 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}